Latest news with #MedicalMarijuanaandCannabidiolResearchExpansionAct
Associated Press
01-05-2025
- Business
- Associated Press
DEA Unconstitutional Marijuana Hearing - MMJ to File Emergency Injunction and Suit for Irreparable Harm
'We are not just challenging DEA policy, we are defending the Constitution said Duane Boise, CEO of MMJ BioPharma Cultivation. The DEA cannot sidestep Supreme Court precedent and force us into a hearing. The agency is running a closed loop of power, Boise added, they investigate, prosecute, judge and override all in-house. That's not justice, that's a rigged game.' WASHINGTON, DC / ACCESS Newswire / May 1, 2025 / MMJ BioPharma Cultivation announced today that it will file for an emergency motion for injunctive relief in the U.S. District Court for the District of Rhode Island following a controversial ruling by a DEA Administrative Law Judge (ALJ) to vacate a previously granted stay, thereby green lighting a hearing before a DEA constitutionally flawed tribunal. The company's forthcoming lawsuit will seek to block the DEA's administrative hearing process, which MMJ contends violates the Supreme Court's ruling in Axon Enterprise, Inc. v. FTC, and represents irreparable harm to its constitutional rights. Axon and the Constitutional Crisis The Axon decision, handed down by the U.S. Supreme Court in 2023, established that federal courts may hear structural constitutional challenges to administrative agencies without requiring parties to exhaust agency proceedings first. MMJ argues that the DEA's internal administrative process-led by ALJs who are unconstitutionally insulated from presidential removal-defies this ruling. 'We are not just challenging policy; we are defending the Constitution,' said Duane Boise, CEO of MMJ BioPharma Cultivation. 'The DEA cannot sidestep Supreme Court precedent and force us into a hearing that, by their own partial admission, is unconstitutional.' From Delay to Damage MMJ has been seeking DEA approval since 2018 to manufacture pharmaceutical-grade cannabis for FDA clinical trials aimed at treating Huntington's Disease and Multiple Sclerosis. Despite: ...MMJ has waited more than 2,300 days, well beyond the 60-day review period mandated by the Medical Marijuana and Cannabidiol Research Expansion Act (MCREA). Now, with the DEA insisting on proceeding with a hearing before an ALJ system MMJ contends is structurally unconstitutional, the company is seeking judicial intervention to prevent what it sees as an 'illegal and biased process.' Alleged Irreparable Harm The emergency injunction will argue that forcing MMJ to participate in this proceeding now would cause: 'This is a direct threat to the right of every American business to a fair process under the law,' Boise added. 'We will not submit to an unconstitutional tribunal.' What's Next MMJ's legal team plans to file the emergency motion and accompanying complaint in the coming days. The action seeks: MMJ's leadership emphasized that this fight is not just about one company-but about accountability at the highest levels of government. 'We are going to federal court to say enough is enough,' said Boise. 'It's time the DEA follows the law-not rewrites it.' MMJ is represented by attorney Megan Sheehan. CONTACT: Madison Hisey [email protected] 203-231-8583 SOURCE: MMJ International Holdings press release
Associated Press
20-04-2025
- Business
- Associated Press
DEA MARIJUANA SCAM: As DEA Cannabis Program Implodes This 4/20, MMJ Stands Alone in Pursuit of Real Medicine
MMJ's DEA lawsuit continues moving through the federal courts. The 8 organizations who have been issued DEA federal cannabis registrations since 2021, all are incapable of growing pharmaceutical-grade marijuana and 7 are now either inactive or bankrupt. WASHINGTON, DC / ACCESS Newswire / April 20, 2025 / As the nation marks April 20 or '4/20,' the unofficial cannabis holiday long associated with marijuana reform, cultural awareness, and patient advocacy, new revelations expose a scandal at the heart of America's DEA federal cannabis research policy. The 8 companies granted marijuana registrations by the U.S. Drug Enforcement Administration (DEA) since 2021, the only one, MMJ BioPharma Cultivation is actively pursuing FDA-compliant, pharmaceutical-grade marijuana development. The others are either inactive, bankrupt or never began cultivation at all. Despite being the only registrant aligned with federal pharmaceutical drug development standards, MMJ BioPharma's application has been delayed since 2018 - a staggering violation of the Medical Marijuana and Cannabidiol Research Expansion Act (MCREA), which requires the DEA to act within 60 days. 'This is not a backlog - this is a blockade. The DEA's inaction has destroyed scientific opportunities and patient hope. Seven years is not a delay - it's deliberate DEA obstruction' said Duane Boise, CEO of MMJ BioPharma Cultivation. 4/20: From Celebration to DEA Epitome Of Ineptitude April 20 has long been a symbol of cannabis progress and patient empowerment. But in 2025, it also marks the failure of America's regulatory framework due to bureaucrats at the DEA that have not delivered. Meet Thomas Prevoznik, Deputy Administrator, Matthew Strait, Deputy Administrator Policy and Aarathi Haig, DEA attorney now under investigation for ethical violations. While the DEA continues to posture about promoting research, the facts tell a different story: MMJ BioPharma Cultivation: Still Waiting While Others Vanish MMJ BioPharma is the only registrant to: Despite these accomplishments, the DEA has yet to issue MMJ's bulk manufacturing registration. DEA's Marijuana Research Program: A Roster of Failure Calls for Action on 4/20 In light of the program's implosion, MMJ BioPharma and patient advocates are calling for: 'On this 4/20, Americans should not be celebrating cannabis reform - they should be demanding accountability, Boise added. 'The DEA's marijuana program isn't just broken. It's a scam - and suffering patients are paying the price.' MMJ is represented by attorney Megan Sheehan. CONTACT: Madison Hisey [email protected] 203-231-8583 SOURCE: MMJ International Holdings press release
Yahoo
20-04-2025
- Business
- Yahoo
DEA MARIJUANA SCAM: As DEA Cannabis Program Implodes This 4/20, MMJ Stands Alone in Pursuit of Real Medicine
MMJ's DEA lawsuit continues moving through the federal courts. The 8 organizations who have been issued DEA federal cannabis registrations since 2021, all are incapable of growing pharmaceutical-grade marijuana and 7 are now either inactive or bankrupt. WASHINGTON, DC / / April 20, 2025 / As the nation marks April 20 or "4/20," the unofficial cannabis holiday long associated with marijuana reform, cultural awareness, and patient advocacy, new revelations expose a scandal at the heart of America's DEA federal cannabis research policy. The 8 companies granted marijuana registrations by the U.S. Drug Enforcement Administration (DEA) since 2021, the only one, MMJ BioPharma Cultivation is actively pursuing FDA-compliant, pharmaceutical-grade marijuana development. The others are either inactive, bankrupt or never began cultivation at all. Despite being the only registrant aligned with federal pharmaceutical drug development standards, MMJ BioPharma's application has been delayed since 2018 - a staggering violation of the Medical Marijuana and Cannabidiol Research Expansion Act (MCREA), which requires the DEA to act within 60 days. "This is not a backlog - this is a blockade. The DEA's inaction has destroyed scientific opportunities and patient hope. Seven years is not a delay - it's deliberate DEA obstruction" said Duane Boise, CEO of MMJ BioPharma Cultivation. 4/20: From Celebration to DEA Epitome Of Ineptitude April 20 has long been a symbol of cannabis progress and patient empowerment. But in 2025, it also marks the failure of America's regulatory framework due to bureaucrats at the DEA that have not delivered. Meet Thomas Prevoznik, Deputy Administrator, Matthew Strait, Deputy Administrator Policy and Aarathi Haig, DEA attorney now under investigation for ethical violations. While the DEA continues to posture about promoting research, the facts tell a different story: 7 of 8 registrants are non-operational or irrelevant to medical science The only viable pharmaceutical applicant MMJ remains blocked MCREA's 60-day deadline has been ignored for over 2,300 days MMJ BioPharma Cultivation: Still Waiting While Others Vanish MMJ BioPharma is the only registrant to: Submit FDA Investigational New Drug (IND) applications Receive FDA Orphan Drug Designation for Huntington's Disease Develop a THC/CBD softgel for Huntington's Disease and MS Build a federally compliant cultivation facility Complete and pass DEA pre-registration inspections DEA Issued Schedule 1 registration to MMJ Labs Despite these accomplishments, the DEA has yet to issue MMJ's bulk manufacturing registration. DEA's Marijuana Research Program: A Roster of Failure Company Status Notes MMJ BioPharma Cultivation ✅ Active Still waiting for DEA to issue registration; only company pursuing FDA clinical trials with softgel capsule Maridose (Maine) ❌ Inactive Not growing, only 1,100 sq ft of space Scottsdale Research Institute ❌ Inactive No marijuana being cultivated Bright Green Corp ❌Surrendered Never grew; relinquished registration Royal Emerald Pharmaceuticals ❌ Inactive Rumored bankruptcy Groff NA Hemplex ❌ Inactive Ceased operations University of Mississippi ⚠️ Poor Quality Substandard marijuana, decades-old monopoly BRC (Biopharmaceutical Research Co.) ⚠️ Limited Activity Growing a small number of plants, not FDA-focused Irvine Labs ⚠️ Limited Activity Minimal cultivation, no pharmaceutical output Calls for Action on 4/20 In light of the program's implosion, MMJ BioPharma and patient advocates are calling for: Immediate approval of MMJ BioPharma Cultivation's stalled application A DOJ Office of Inspector General investigation Full congressional oversight hearings A formal audit of all DEA marijuana registrants since 2021 "On this 4/20, Americans should not be celebrating cannabis reform - they should be demanding accountability, Boise added. "The DEA's marijuana program isn't just broken. It's a scam - and suffering patients are paying the price." MMJ is represented by attorney Megan Sheehan. CONTACT:Madison Hiseymhisey@ SOURCE: MMJ International Holdings Related Documents: Image 4-18-25 at 11.00 AM View the original press release on ACCESS Newswire Sign in to access your portfolio
Associated Press
15-04-2025
- Business
- Associated Press
The DEA Is Defying Supreme Court Axon in MMJ's Cannabis Case - Is DEA a rogue agency?
Duane Boise CEO of MMJ stated 'Let's be clear: this isn't just administrative overreach. This is defiance of the Supreme Court by a law enforcement agency. The DEA, tasked with upholding the law, is now actively undermining it'. WASHINGTON, DC / ACCESS Newswire / April 15, 2025 / The Supreme Court has spoken. In its landmark Axon Enterprise, Inc. v. FTC decision, the Court affirmed that Americans have the right to challenge unconstitutional agency structures in federal court before enduring prolonged and potentially unlawful administrative proceedings. This ruling was meant to be a shield - protecting individuals and companies from bureaucratic abuse. But the Drug Enforcement Administration (DEA) has decided it doesn't care. In its ongoing battle with MMJ BioPharma Cultivation, the DEA has done more than ignore Axon - it's practically dared the judiciary and the public to hold it accountable. Despite conceding that its own administrative law judges (ALJs) are unconstitutionally insulated from removal , the DEA continues to force MMJ through a regulatory meat grinder. Duane Boise CEO of MMJ stated 'Let's be clear: this isn't just administrative overreach. This is defiance of the Supreme Court by a law enforcement agency. The DEA, tasked with upholding the law, is now actively undermining it'. In Axon, the Court declared that when an agency's structure is alleged to be unconstitutional, federal courts can and should intervene immediately - no need to wait years while the flawed process grinds forward. Yet in MMJ's case, the DEA has done precisely the opposite: dismissing MMJ's federal constitutional challenge by arguing that no 'irreparable harm' was done. This argument is a slap in the face not only to MMJ but to the judiciary itself. Axon wasn't about requiring proof of harm - it was about protecting rights from being violated in the first place. The DEA's continued reliance on the Administrative Law Judge hearing process admits that the judges are improperly shielded from removal renders its entire process suspect. And it gets worse. MMJ Biopharma Cultivation's application to grow and research cannabis to manufacture cannabis-derived medicines for debilitating diseases like Huntington's and Multiple Sclerosis has been sitting idle since 2018. This is despite Congress mandating in the Medical Marijuana and Cannabidiol Research Expansion Act (MCREA) that DEA respond within 60 days. The DEA didn't just miss a deadline - it ignored federal law. Add to that the stunning revelation that DEA's lead counsel, Aarathi Haig, is ineligible to practice law in New Jersey - a breach of 28 U.S.C. § 530B - and what emerges is a pattern of disregard for legality, ethics, and public duty. This situation has even prompted scrutiny from legal ethics experts and calls for audits and congressional hearings. The agency's failure to follow Axon is not a bureaucratic oversight. It is a boldfaced assertion that the rules don't apply when the DEA doesn't want them to. This is not just about MMJ - it is about the legitimacy of every administrative action the DEA takes under structurally unconstitutional authority. If the courts allow this to stand, the Supreme Court's ruling in Axon becomes meaningless. And if Congress stays silent, it signals that executive agencies can defy judicial authority without consequence. America is watching. Patients are watching. The courts are watching. And the DEA must be held to account. For MMJ BioPharma Cultivation, this is a fight for justice. For the rest of us, it's a fight for the Constitution. The question now is: Will the law enforcement agency charged with enforcing justice finally submit to it? The DEA's alleged obstruction, involving officials like Thomas Prevoznik, Matthew Strait and Aarathi Haig raises serious concerns about whether the agency is acting as a rogue entity, prioritizing its own agenda over the rule of law and the needs of patients. MMJ is represented by attorney Megan Sheehan. CONTACT: Madison Hisey [email protected] 203-231-8583 SOURCE: MMJ International Holdings press release
